Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1745-1748

  Deutsch, Melanie ^a   Koskinas, John ^a   Tzannos, Konstatinos ^a   Vassilopoulos, Dimitrios ^a   Mailis, Antonis ^a   Tolis, George ^a   Hadziyannis, Stephanos ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Chronic hepatitis C; Hashimoto encephalopathy; Pegylated interferon alfa 2b

Indexed keywords

CORTICOSTEROID; DIAZEPAM; INSULIN; PEGINTERFERON ALPHA2B; PHENYTOIN; PREDNISOLONE; RIBAVIRIN; THYROID ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BRAIN DISEASE; CASE REPORT; CHRONIC HEPATITIS; ELECTROENCEPHALOGRAM; FEMALE; HASHIMOTO DISEASE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; MENTAL DISEASE; NEUROIMAGING; NEUROPSYCHIATRY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; NEUROTOXICITY SYNDROMES; RIBAVIRIN;

EID: 25844469966     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G144     Document Type: Article

References (17)

1. Brain L, Jellinek EH, Ball K. Hashimoto's disease and encephalopathy. Lancet 1966;2:512-4.
2. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003;60:164-71.
3. Taylor SE, Garalda ME, Tudor-Williams G, Martinez-Alier N. An organic cause of neuropsychiatrie illness in adolescence. Lancet 2003; 361:572.
4. Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996;234:585-93.
5. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M. High prevalence of serologic markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
6. Deutsch M, Dourakis S, Manesis EK, Giustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology 1997;26:206-10.
7. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-9.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J Hepatol 1996;24:48-51.
10. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002;32:163-73.
11. Ghika-Schmid F, Ghika J, Regli F, Dworak N, Bogousslavsky J, Stadler C, et al. Hashimoto's myoclonic encephalopathy: an underdiagnosed treatable condition? Mov Disord 1996;11:555-62.
12. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
13. Shaw PJ, Walls TJ, Newmann PK, Cleland PG, Cartlidge NE. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers. Neurology 1991;41:228-33.
14. Chen HC, Masharani U. Hashimoto's encephalopathy. South Med J 2000;93:504-6.
15. Schauble B, Castillo PR, Boeve BF, Westmoreland BF. EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clin Neurophysiol 2003;114:32-7.
16. McCabe DJ, Burke T, Connoly S, Hutchinson M. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto encephalopathy. Neurology 2000;54:737-9.
17. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.